Introduction
Perampanel (PER) is a new antiepileptic drug that suppresses neuronal hyperexcitability by selectively and non-competitively inhibiting AMPA receptors. Previous reports have indicated that antiepileptic drugs place patients at risk for the onset of delirium [1] ; however, to date, there have been no reported cases of delirium associated with PER use. In the present report, we discuss a case of symptomatic epilepsy in which delirium appeared following administration of PER and completely resolved following discontinuation of PER. Written consent has been obtained from the patient for the publication of this case report.
Case
On day 42, CBZ was discontinued due to hyponatremia. After cessation of the drug, serum sodium maintained normal value. However, because focal motor seizures resumed on day 47, the patient was started on PER (2 mg/day) on day 48. Following another focal motor seizure on day 94, PER was increased to 4 mg/ day. Beginning around day 95, the patient began to experience drowsiness and irritability. On day 111, PER was increased to 8 mg/ day. On the following day, the patient exhibited sudden-onset cognitive impairment, including attentional impairment, disorientation, memory impairment, confusion during conversation, and abnormal movements. The diurnal variation in these symptoms was striking. As the neurosurgeon suspected dementia, the patient was referred to our hospital's psychiatric department and underwent examination on day 118, at which time his symptoms were still present. Electroencephalography (EEG) revealed no epileptic discharge, and the basic rhythm demonstrated thetarange activity (Fig. 1) . Based on criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition, the patient was diagnosed with delirium. The patient received 16 points on the Delirium Rating Scale-Revised-98 (DRS-R-98) and 15/30 points on the Mini Mental State Examination (MMSE).
Further testing was performed to explore the cause of the patient's delirium. Blood testing revealed no abnormalities in levels of electrolytes including serum sodium, thyroid function, ammonia, vitamin B 1 , or other components. Brain MRI revealed no new lesions. In addition to PER, the patient was receiving treatment with LEV (3,000 mg/day), nifedipine (20 mg/day), and rosuvastatin calcium (2.5 mg/day). However, because he had been taking these medications for over a year, they were excluded as the cause of the delirium. Based on the case details, we strongly suspected PER-induced delirium. PER was therefore discontinued, and the patient was started on lacosamide at a dosage of 100 mg/ day, following which his neurological symptoms gradually improved. On day 125, his disorientation and abnormal movements had resolved. On day 135, his DRS-R-98 score was 0, while his MMSE score was 30, and his symptoms of delirium had completely resolved. EEG activity had normalized, and a basic alpha rhythm was observed (Fig. 1) . Thus, the patient received a final diagnosis of PER-induced delirium.
Discussion
To date, there have been no reports of delirium associated with PER use, and the risk of delirium is not noted in the package insert for PER. Therefore, we suspect that this is the first reported case of PER-induced delirium. Furthermore, although some previous reports have suggested that PER does not impair general cognitive function [2] , the present case indicates that PER use may be associated with the onset of delirium as well as a severe and reversible decline in general cognitive function.
PER exerts an anti-epilepsy effect, suppressing neuronal hypersensitivity by selectively and non-competitively inhibiting AMPA receptors, which are thought to play a key role in several cognitive functions such as learning and memory [3] . One previous study reported that intravenous administration of the competitive AMPA receptor antagonist ZK200775 causes a reduction of consciousness [4] , suggesting that drugs that inhibit AMPA receptors have the potential to produce impairments in consciousness. Although we were unable to identify the precise mechanism by which PER caused delirium, we hypothesize that delirium occurred due to the primary medicinal action of AMPA receptor inhibition by PER.
Conclusion
Clinicians should remain aware of the potential for delirium when prescribing PER. Further research should be conducted to elucidate the mechanisms by which PER induces delirium.
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